Section Arrow
Quote
BRTX.NASDAQ
- BioRestorative Therapies
(Financial Status)
Quotes are at least 15-min delayed:2026/05/22 17:29 EDT
After Hours
Last
 0.208
0 (0.00%)
Bid
0.208
Ask
0.2085
High 0.2095 
Low 0.2016 
Volume 45.95K 
Regular Hours (Closed)
Last
 0.208
+0.015 (+7.77%)
Day High 
0.21 
Prev. Close
0.193 
1-M High
0.262 
Volume 
1.56M 
Bid
0.208
Ask
0.2085
Day Low
0.1869 
Open
0.189 
1-M Low
0.1593 
Market Cap 
4.92M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.19 
20-SMA 0.21 
50-SMA 0.24 
52-W High 2.045 
52-W Low 0.1593 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.06/-0.37
Enterprise Value
5.08M
Balance Sheet
Book Value Per Share
0.12
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
416.00K
Operating Revenue Per Share
0.01
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
GOVXGeoVax Labs Inc.3.64+0.89+32.36%-- 
After Hours 3.65 +0.01 +0.27%
MTVAMetaVia Inc.3.85+0.98+34.15%-- 
After Hours 3.55 -0.3 -7.79%
AKTXAkari Therapeutics Plc18.27+13.13+255.45%-- 
After Hours 13.74 -4.53 -24.79%
LIMNLiminatus Pharma Inc0.1694-0.0766-31.14%-- 
After Hours 0.163 -0.0064 -3.78%
IOVAIovance Biotherapeutics4.11+0.41+11.08%-- 
After Hours 4.07 -0.04 -0.97%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.